A Phase 1/2, Open-Label Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome

Trial Profile

A Phase 1/2, Open-Label Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Fragile X syndrome
  • Focus Adverse reactions
  • Acronyms FAB-C
  • Sponsors Zynerba Pharmaceuticals
  • Most Recent Events

    • 07 Aug 2017 According to a Zynerba Pharmaceuticals media release, top-line data is anticipated in end of September 2017.
    • 01 Aug 2017 According to a Zynerba Pharmaceuticals media release, dosing is ongoing in the phase 2 part of this trial.
    • 20 Jul 2017 Status changed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top